Results 31 to 40 of about 43,170 (263)

Pharmacogenetics of dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes mellitus: A review

Терапевтический архив
The review addresses publications on genetic polymorphisms that potentially impact the effectiveness of therapy with hypoglycemic drugs of the dipeptidyl peptidase-4 inhibitor group.
Iuliia G. Samoilova, Olga E. Vaizova, Anastasia E. Stankova, Mariia V. Matveeva, Daria V. Podchinenova, Dmitry A. Kudlay, Anastasiia A. Borozinets, Tatyana A. Filippova, Ivan R. Grishkevich, Anastasia V. Partala, Diana A. Gerasimova   +10 more
doaj   +1 more source

Urate-lowering effects of dipeptidyl peptidase-4 inhibitors

Сахарный диабет, 2020
Hyperuricemia is an increase of uric acid (UA) concentration in blood serum >420 pmol/L in men or >360 pmol/L in women and is considered to be a common biochemical abnormality. This condition shows that the extracellular fluid is oversaturated with
Taras S. Panevin, Olga V. Zhelyabina, Maxim S. Eliseev, Marina V. Shestakova   +3 more
doaj   +1 more source

Dipeptidyl Peptidase-4 Inhibitor

Korean Journal of Medicine, 2014
Recent advances in incretin biology have led to the development of a new class of oral anti-diabetic drugs. To date, there are two known incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), of which the former is a more important therapeutic target for type 2 diabetes.
openaire   +1 more source

An Engineered HR1‐Stem Helix‐HR2 Trimeric Platform for Developing Broad‐Spectrum Coronavirus Vaccines

Advanced Science, EarlyView.
Sun et al. report a self‐assembling trimeric subunit vaccine platform termed RHS, which integrates the JN.1 receptor‐binding domain (RBD) with the heptad repeat 1 (HR1), stem helix (SH), and heptad repeat 2 (HR2) regions. The SARS‐CoV‐2 RHS vaccine elicits variant‐reactive RBD‐specific antibodies and cross‐reactive SH‐specific antibodies against ...
Xikui Sun, Junhao Fan, Xiaolu Xie, Yuting Shi, Xiaoqing Liu, Tiefeng Xu, Sidi Yang, Keda Shi, Chengshu Xie, Shixiong Li, Siwen Chen, Ruoxi Cai, Ping He, Yuzhen Ye, Tao Chen, Xiancai Ma, Chunmei Li, Jingyou Yu, Deyin Guo   +18 more
wiley   +1 more source

Association between Serum Dipeptidyl Peptidase-4 Concentration and Obesity-related Factors in Health Screen Examinees

Journal of Obesity & Metabolic Syndrome, 2017
Background : Dipeptidyl peptidase-4 (DPP-4) is an aminopeptidase that inhibits the enzymatic degradation of glucagon-like peptide-1, glucose-dependent insulinotropic polypeptides, neuropeptides, and various chemokines.
Ji Yeon Lee, Byoung Kuk Jang, Min Kyung Song, Hye Soon Kim, Mi-Kyung Kim   +4 more
doaj   +1 more source

The role of dipeptidyl peptidase - 4 inhibitors in diabetic kidney disease

Frontiers in Immunology, 2015
Despite major advances in the understanding of the molecular mechanisms that underpin the development of diabetic kidney disease, current best practice still leaves a significant proportion of patients with end stage kidney disease requiring renal ...
Usha ePanchapakesan, Carol ePollock
doaj   +1 more source

Dipeptidyl peptidase-4 and kidney fibrosis in diabetes

Fibrogenesis & Tissue Repair, 2016
Diabetic nephropathy (DN) is the most common cause of end-stage kidney disease worldwide and is associated with increased morbidity and mortality in patients with both type 1 and type 2 diabetes. Recent evidence revealed that dipeptidyl peptidase-4 (DPP-4) inhibitors may exhibit a protective effect against DN. In fact, the kidney is the organ where the
Shi, Sen, Koya, Daisuke, Kanasaki, Keizo
openaire   +2 more sources

Reframing the Gut–Brain Axis: The Gut Wall as a Neural Immune Interface in Multiple Sclerosis and Autoimmune Neurological Diseases

Annals of Neurology, EarlyView.
Gut wall physiology in multiple sclerosis (MS) and autoimmune neurologic diseases remains underexplored but may span gut barrier dysfunction, enteric glial targeting, mucosal immune dysregulation, and autoimmune targets within the enteric nervous system (ENS).
Federico Montini, Sean J. Pittock, Laura Cacciaguerra, Howard L. Weiner, Luke A. Schwerdtfeger   +4 more
wiley   +1 more source

Repositioning of dipeptidyl peptidase-4 inhibitors and glucagon like peptide-1 agonists as potential neuroprotective agents

Neural Regeneration Research, 2019
Repositioning of dipeptidyl peptidase-4 inhibitors and glucagon like peptide-1 receptor agonists is a breakthrough in the field of neural regeneration research increasing glucagon like peptide-1 bioavailability, hence its neuroprotective activities.
Shaker A Mousa, Bassam M Ayoub
doaj   +1 more source

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source